Cambridge Investment Research Advisors
BIOR

Cambridge Investment Research Advisors’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60
Closed -$7K – 3247
2022
Q3 		$7K Hold
60
– – ﹤0.01% 3031
2022
Q2 		$11K Hold
60
– – ﹤0.01% 3017
2022
Q1 		$18K Buy
+60
New +$22.8K ﹤0.01% 3122

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Cambridge Investment Research Advisors's BIOR Position: Q4 2022 in Review

Cambridge Investment Research Advisors sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2022, closing a stake of 60 shares — an estimated $7K sold.

Cambridge Investment Research Advisors first reported a position in BIOR in Q1 2022 and held it in 3 quarters. The position peaked at $18K in Q1 2022. 42 funds tracked by Wall St. Rank hold BIOR as of Q4 2022.

  • Cambridge Investment Research Advisors reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 60 Biora Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $7K.
  • Cambridge Investment Research Advisors first reported a position in Biora Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Biora Therapeutics, Inc. Common Stock position peaked at $18K in Q1 2022.
  • 42 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.